24 HR lamotrigine 200 MG Extended Release Oral Tablet

1 INDICATIONS AND USAGE Lamotrigine extended-release tablets are indicated for: adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. (1.1) conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug. (1.2) Limitation of use: Safety and effectiveness in patients younger than 13 years have not been established. (1.3) 1.1 Adjunctive Therapy Lamotrigine extended-release tablets are indicated as adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. 1.2 Monotherapy Lamotrigine extended-release tablets are indicated for conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug (AED). Safety and effectiveness of lamotrigine extended-release tablets have not been established (1) as initial monotherapy or (2) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. 1.3 Limitation of Use Safety and effectiveness of lamotrigine extended-release tablets for use in patients younger than 13 years have not been established.

Amneal Pharmaceuticals LLC

FDA Reported Adverse Reactions
`[1] fatigue` `[2] dyspnoea` `[3] off label use` `[4] drug ineffective` `[5] pain` `[6] nausea` `[7] headache` `[8] arthralgia` `[9] diarrhoea` `[10] pyrexia`

4 years ago

ROUND BLUE A 986

16 HOW SUPPLIED/STORAGE AND HANDLING Lamotrigine extended-release tablets USP, 25 mg, are supplied as yellow, round shaped, film-coated tablets debossed with “A” above “949” on one side and plain on the other side. They are available as follows: Bottles of 30: NDC 65162-949-03 Bottles of 90: NDC 65162-949-09 Lamotrigine extended-release tablets USP, 50 mg, are supplied as green, round shaped, film-coated tablets debossed with “A” above “956” on one side and plain on the other side. They are available as follows: Bottles of 30: NDC 65162-956-03 Bottles of 90: NDC 65162-956-09 Lamotrigine extended-release tablets USP, 100 mg, are supplied as beige, round shaped, film-coated tablets debossed with “A” above “958” on one side and plain on the other side. They are available as follows: Bottles of 30: NDC 65162-958-03 Bottles of 90: NDC 65162-958-09 Lamotrigine extended-release tablets USP, 200 mg, are supplied as blue, round shaped, film-coated tablets debossed with “A” above “986” on one side and plain on the other side. They are available as follows: Bottles of 30: NDC 65162-986-03 Bottles of 90: NDC 65162-986-09 Lamotrigine extended-release tablets USP, 250 mg, are supplied as purple, capsule shaped, film-coated tablets debossed with “AN 988” on one side and plain on the other side. They are available as follows: Bottles of 30: NDC 65162-988-03 Bottles of 90: NDC 65162-988-09 Lamotrigine extended-release tablets USP, 300 mg, are supplied as gray, capsule shaped, film-coated tablets debossed with “AN 990” on one side and plain on the other side. They are available as follows: Bottles of 30: NDC 65162-990-03 Bottles of 90: NDC 65162-990-09 Storage Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

More pills like ROUND A 986

Related Pills

24 HR lamotrigine 300 MG Extended Release Oral Tablet

Amneal Pharmaceuticals LLC

24 HR lamotrigine 250 MG Extended Release Oral Tablet

Amneal Pharmaceuticals LLC

24 HR lamotrigine 100 MG Extended Release Oral Tablet

Amneal Pharmaceuticals LLC

24 HR lamotrigine 50 MG Extended Release Oral Tablet

Amneal Pharmaceuticals LLC

24 HR lamotrigine 25 MG Extended Release Oral Tablet

Amneal Pharmaceuticals LLC

24 HR lamotrigine 200 MG Extended Release Oral Tablet

Amneal Pharmaceuticals LLC

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site